The Priority Review

Tag

HIP2602

1 story

  1. Clinical trials

    Hanmi registers Phase 3 trial of HIP2602 in erectile dysfunction

    The study, led by Hanmi Pharmaceutical Company Limited, plans to enroll 225 participants and begin in October 2026. It is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of HIP2602 in erectile dysfunction patients.